Biocon Limited has informed the Exchange about Transcript

Biocon reported Q1 FY26 operating revenue of INR 3,942 crore, up 15% year-on-year (like-for-like), led by 18% growth in biosimilars (INR 2,458 crore), 11% growth in CRDMO/Syngene (INR 875 crore), and 6% growth in generics (INR 697 crore). Core EBITDA rose 11% YoY to INR 1,003 crore at a 25% margin, with biosimilars EBITDA up 36% and margins expanding ~300 bps on operating leverage. Key milestones included US FDA approval of Kirsty (first interchangeable rapid-acting insulin), launch of Yesafili in Canada, and EU/UK approvals for biosimilar Denosumab. The company completed a INR 4,500 crore QIP (its first equity raise since the 2004 IPO), using proceeds to repay Goldman Sachs debt and increase its stake in Biocon Biologics to ~78%. Generics margins were temporarily pressured (~INR 60 crore/quarter) by new facility ramp-up costs, but management expects strong double-digit growth and margin recovery from H2 FY26.